Peran Metformin terhadap Dislipidemia Aterogenik pada Sindroma Metabolik dengan Diabetes Mellitus Tipe-2 yang terawat jelek

Sugiarto Sugiarto, Diding HP Diding HP, Guntur H Guntur H, Marsetio D Marsetio D, Tjokroprawiro A Tjokroprawiro A

Abstract


Sindroma Metabolik dengan Diabetes Mellitus tipe-2 [SIMET-DM] merupakan kelompok faktor risiko kardiometabolik dan mempunyai peranan terhadap peningkatan penyakit kardiovaskular. Metformin merupakan obat yang mempunyai efek pleiotropik yang meliputi efek metabolik, kardiovaskular dan anti-kanker. Penelitian ini dimaksudkan untuk mengujiapakah metformin mempunyai  efek kardioprotektif melalui perbaikan dislipidemia aterogenik pada SIMET-DM tipe-2 yang terawat jelek. Penelitian dilakukan dengan metode acak, uji klinik buta-ganda di klinik Penyakit Dalam RSUD Dr Moewardi Surakarta antara bulan Desember 2008 sampai dengan Juli 2009 pada penderita SIMET-DM tipe-2 yang terawat jelek. Empat puluh dua pasien dibagi menjadi dua kelompok yaitu kelompok meformin dan plasebo, masing-masing 21 pasien. Data dianalisis dengan independent samples t-test, dilanjutkan effect size metformin dengan tingkat kemaknaan p <0,05. Hasilnya memperlihatkan bahwa secara bermakna metformin menurunkan LDL-C (p =0,012) dibanding placebo, namun tidak untuk HDL-C (p=0,151), TG (p=0,930), maupun small-denseLDL (p= 0,323). Sebagai simpulan metformin memperlihatkan efek kardioprotektif melalui perbaikan dislipidemia aterogenik (penurunan LDLC) pada SIMET-DM tipe-2 yang terawat jelek

Keywords


Dislipidemia; risiko kardiometabolik; efek pleiotropic; kardioprotektif

Full Text:

PDF

References


Aguiar LGKD, Bahia LR, Villela N, Laflor C, Sicuro F, Wiernsperger N, Bottino D, Bouskela E 2006. Metformin Improved Endothelial Vascular Reactivity in First-Degree Relatives of Type 2Diabetic Patient With Metabolic Syndrome and Normal Glucose Tolerance. Diabetes Care 29: 10831089

Arsenault BJ, Lemieux I, Depress JP, Wareham NJ, Luben R, Kastelein JJP, Khaw KT, Boekholdt M 2007. Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norforlk prospective population study. European Heart Journal 28: 2770-2777.

Benn M, Borge G ,Nordestgaard, Jensen GB, TyjaergHansen A 2007. Improving Prediction of Ischemic cardiovascular Disease in the general population Using Apolipoprotein B: The Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol 27: 661-670

Berry C, Tardift JC, Bourassa MG 2007. Coronary heart disease in patients with diabetes: Part I: Recent advances in prevention and noninvansive management. J Am.Coll.Cardiol 49: 631-642

Brunzell JD 2007. Hypertriglyceridemia.N Engl J Med 357: 1009-1017

Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howaed BV, Stein JH, Witztum JL 2008. Lipoprotein management in patients with cardiometabolic risk.Diabetes Care 31: 811-822

Chan JCN, dan Davidson JA 2007. Mechanisme of vascular protection with metformin. In (Bailey CJ,Campbell IW,Chan JCN, Davidson,JA,Howlett HCS, Ritz P, eds). Metformin: The gold standart, A

scientific hanbook. Canada: John Wiley &Son Ltd, pp 135-152.

Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S 2001. Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients. Diabet Med 18: 828-834

Chen MF, Xie XM, Yang TL, Wang YJ, Zhang XH, Luo BI,Li YJ 2007. Role of asymmetric dimetylarginine in inflammatory reactions by angiotensin II.J Vasc Res 44: 391-402

Defronzo RA 2007. Efficacy. In (Bailey CJ, Campbell IW, Chan JCN, Davidson,JA,Howlett HCS, Ritz P, eds). Metformin: The gold standart, A scientific hanbook. Canada: John Wiley &Son Ltd : 37

Defronzo RA, dan Goodman AM 1995. Efficacy of metformin in patients with non-insulin –dependent diabetes mellitus.N Engl J Med 333: 541-549

Dichtl W, Nilsson L, Goncalves I, Ares MPS, Banfi C, Calara F, Hamstern A, Eriksson P, Nilsson J 1999. Very low-Density Lipoprotein activates Nuclear Factor-?B in Endothelial Cells. Circ Res 84: 10851094

Fonseca V, Desouza C, Asnani S, Jialal I 2004. Nontradisional risk factor for cardiovascular disease in diabetes.Endocrine Review25(1):153-175

Fryer LGD, Parbu-Patel A, Carling D 2002.The Antidiabetic Drugs Rosiglitazone and Metformin Stimulate AMP-activated Protein Kinase through Distinct Signaling Pathways.The Journal of Biological Chemistry 28: 25226-25232

Garber AJ 2000. Attenuating Cardiovascular Risk Factors in Patients with type 2 Diabetes.American Family Physician 62: 2633-2642

Golay A 2008. Review Metformin and body weight. International Journal of Obesity 32: 61-72

Gotto AM, Amarenco P, Assmann G, Carmena R, Davignon J, Fruchart JC, Kastelein JJP, Paoletti R, Tonkin A 2003. Dyslipidemia and Coronary Heart Disease.The ILIB Lipid Handbook for Clinical Practice, 3 rd Edition. International Lipid Information Bureau, New York

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DL, Krauss RM, Savage PJ, Smitk SC, Spertus JJA, and Costa F 2005. Diagnosis and Management of the Metabolic syndrome: An American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752

Jager JD, Kooy A, Lehert PH, Bets D, Wulffele MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJM, Stehouwer CDA 2005. Effects of short-term treatment with on marker of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized,placebo-controlled trial. J Intern Med 257: 100-109

Janiszewski PM, Saunders TJ, Ross R 2008. Themed Review: Lifestyle Treatment of the Metabolic syndrome. American Journal of Lifestyle Medicine 2:99108

Kane JP dan Malloy MJ 1994. Disorder of lipoprotein metabolism : in Francis SG, John D.D (edt) Basic & Clinical Endocrinology. 4 edition, Appleton &Lange ,New Jersey : 649-678

Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ,Wilson PWF,D’Agostino RB, Vasan RS, Robin SJ 2006.Increased small dense low-density lipoprotein particle number.A Prominent feature of the Metabolic Syndrome in Framingham Heart Study.Circulation 113: 20-29

Knowler WC, Barrett-Connor E, Fowler SE, Hamman R, Lachin JM, Walker EA, Nathan DM 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.N Engl J Med 346: 393-403

Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G 2007. Asymmetric Dimethylarginine Predicts cardiovascular Events in Petients With Type 2 Diabetes. Diabetes Care 30: 1834-1839

Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Depress JP 1997. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men.Circulation 95: 69-75

Lele RD 2008. Causation, prevention and reversal of vascular endothelial dysfunction ( (review article). 3 rd National Congress of Indian Stroke Association, 8-9 February, Golden view Resort

Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras N, Bergeron J, Gaudet D, Tremblay G, Prud’homme D, Nadeau A, Despres JP 2000. Hypertrigyceridemic Waist Amarker of the atherogenic metabolic triad (Hyperinsulinemia; Hyperapolipoprotein B; Small, Dense LDL) in Men? Circulation 102: 179-184

Levine YC, Li GK, Michel T 2007. Agonis-modulated Regulation of AMP-activated protein Kinase (AMPK) in Endothelial cells. J Biol Chem 282: 2035120364

Libby P, Ridker PM, Maseri A 2002.Inflamation and Atherosclerosis.Circulation105:1135-1143

Mather KJ, Verma S, Anderson TJ 2001. Improved endothelial function in type 2 diabetes mellitus.J Am Coll Cardiol 37: 1344-1350

Matthael S, Stumvoll M, Kellerer M, Haring HU 2000. Pathophysiology and Pharmacological Treatment of insulin resistance. Endocrine Reviews 21: 585-618.

McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstifield J, Steyn K, Sanderson JF, Hasani M, Volkowa E, Kazmi K, Yusuf S 2008. Lipid, lipoprotein, and apolipoprotein as risk marker of myocardial infarction in 52 countries I the INTERHEART Study):a case-control study. The lancet 372:224-233

Mudd JO, Borlang BA, Jonhston PV, Kral BG, Rouf R, Blumenthal RS, Kwiterovich PO 2007. Beyond LowDensity Lipoprotein Cholesterol: Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease. J Am Coll Cardiol 50: 17351741

Muniyappa R, Montagnani M, Koh KK, Quon MJ 2007. Cardiovascular action of insulin.Endocrine Reviews 28:467-491

Musi N, Hirshman MF, Nygren J, Svanfeltd M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, Moller DE, Thorell A, Goodyer LJ 2002. Metformin Increases AMPActivated

Protein Kinase Activity in Skeletal muscle of subjects with type 2

diabetes.Diabetes52:2074-2081

Nesto RW 2008. LDL Cholesterol lowering in type 2 diabetes : What is the optimum approach ?. Clinical Diabetes26 : 8-13

Opie L 2006. The Metabolic Syndrome–Does it exits?. In(Opie,LH, Kasuga,M,Yellon DM, eds). Diabetes at the limit II. Kyoto: University of Cape Town Press, pp 97-110

Patel S 2008. High-density lipoprotein: The next frontier in lipid management( editorials). MJA: 189: 421-22

Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB 2005. Non-High-Density Lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in Men.Circulation112: 33753383

PERKENI 2006. Konsensus pengelolaan dan pencegahan diabetes mellitus tipe-2 di Indonesia 2006. Juni-2006, Jakarta

Ren T, He J, Jiang H, Zu L, Pu S, Guo X, XuG 2006. Metformin reduces lipolisis in primary rat adipocytes stimulation by tumor necrosis factor-? or isoproterenol. Journal of Molecular Endocrinology 37: 175-183

Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM,

Heine RJ, Horton ES, Kawamori 2008. Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk : An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93:3671-3689

Ross R 1999. Atherosclerosis-An inflammatory Disease N Engl J Med 340: 115-126

Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M,Ito S, Ogai A, Asakura M,Kim J, Minamino T,Takashima S,Sanada S,Sugimachi M,Komamura K,Mochizuki N, Kitakaze M 2009. Metformin prevents progression of heart failure in dogs (Abstract). Circulation 119: 2568-2577

Schwimmer JB, Middleton MS, Deutsch R, Lavine JE 2005. Aphase 2 clinical trial of metformin as atreatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther 21: 871-879

Shishehbor MH, dan Bhatt DL 2004. Inflammation and atherosclerosis.Current Atherosclerosis Reports 6: 131139

Smilde TJ, Wissen SV, Wollersheim H, Trip MD, Kastelein JJP, Stalenhoef AFH 2001. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomized, double-blind trial. Lancet; 357: 577-581

Srinivasan S, Ambler GR, Baur LA, Ganett SP, Tepsa M, Yap F, Ward GM, Cowell CT 2006. Randomized, Controlled Trial of Metformin for Obesity and Insuli resistance in Children and Adolecents: Improvement in Body Composition and Fasting insulin.J Clin Endocrinol Metab 91: 2074-2080

Tandon VR 2007. Review Article. Metformin therapy : Benefits beyond glycemic control. Int J Diab Ctries 27: 1-4

Toyoda T, Hayashi T, Miyamoto L, Yonemitsu S, Nakano M, Tanaka S, Ebihara K, Masuzaki H, Hosoda K, Inoue G, Otaka A, Sato K, Funshiki T, Nakao K 2004. Possible involvement of the ? 1 isosform of 5’ AMP-activated protein kinase in oxidative stress-stimulated glucose transport in skeletal muscle. Am J Physiol Endocrinol Metab287:E 166-173

Tjokroprawiro A 2004. New strategy for the treatment of T2DM the roles of fixed oral agent combination Dalam: Naskah lengkap Surabaya diabetes Update-XIII, Surabaya, 21-22 Februari:17-30

Tjokroprawiro A 2007A.Cardiometabolic risk factor in patients with Diabetes (therapeutic approach with novel FDC- limepiride/Metformin.Naskah Lengkap

Scientific Symposium New insights into the Management of Diabetic patients with Cardio-Metabolic Risk (CMR). Surabaya, 27 October

Tjokroprawiro A 2008. The trend in emerging lifestyle- related disease in Indonesia. Kobe Association for the study of food and health Kasfah memorial meeting, Kobe, 5 juli 2008.

Tjokroprawiro A 2009. Capita Selecta in Diabetes Mellitus-2009 (Based on Updates and Clinical Experiences). Dalam: Surabaya Diabetes Update –XIX (SDU-IX), Metabolic Cardiovascular Disease Surabaya Update-5 (MECARSU-5), Surabaya, 6-8 November Vitale C, Mercuro G,

Cornoldi A, Fini M, Volterrani M, Rosano GMC 2005. Metformin improves endothelial function in patients with metabolic syndrome. Journal of Internal Medicine 258:250-256

Wascher TC 2003. Diabetes Mellitus-How to Prevent MacrovascularDisease ? J Cardiol 10: 149-151

Welllen KE, dan Hotarmisligil GS 2005. Inflammation, stress and diabetes.J Clin Invest 115: 1111-1119

Zhang M, Zuccollo A, Hou X, Nagata D, Waish K, Hercovitz H, Brecher P, Ruderman NB, Cohen RA 2004. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulinresistance human HepG2 cells. J Biol Chem 279: 47898-47905

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyer LJ, Moller DE 2001.Role of AMP-activated protein kinase in mechanism of metformin action.J Clin Invest 108: 1167-1174

Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG, Schlattner U, Neumann D, Bromnlee M, Freeman MB, Goldman MH 2004. Activation of the AMP-activated Protein Kinase by the Anti-diabetic Drugh Metformin in vivo.The Journal of Biological Chemistry 42: 43940- 43951




DOI: https://doi.org/10.33476/jky.v17i3.212

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 YARSI Medical Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

__________________________________________________________________________________________

Copyright of YARSI Medical Journal.

Powered by OJS.

Creative Commons License

This work is licensed under a Creative Commons Attribution- NonCommercial 4.0 International License.